Welcome to our dedicated page for Vaxart news (Ticker: VXRT), a resource for investors and traders seeking the latest updates and insights on Vaxart stock.
Vaxart Inc. (VXRT) is a clinical-stage biotechnology company pioneering oral tablet vaccines for infectious diseases. This page aggregates official announcements, financial disclosures, and scientific developments related to its recombinant vaccine platform and clinical pipeline.
Investors and researchers will find timely updates on clinical trial progress, regulatory milestones, and strategic partnerships. Our curated collection includes earnings reports, manufacturing updates, and peer-reviewed research findings – all essential for evaluating Vaxart's position in the competitive vaccine market.
Key content focuses on tablet vaccine efficacy data, FDA communications, intellectual property developments, and comparative analyses of mucosal immunization approaches. Bookmark this page to monitor Vaxart's progress in redefining vaccine administration through its temperature-stable oral delivery system.
SOUTH SAN FRANCISCO, Calif., March 29, 2023 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) announced presentations by Dr. Sean Tucker and Dr. James F. Cummings at the World Vaccine Congress Washington 2023 on April 5 and 6, 2023. Dr. Tucker will discuss advancements in oral tablet vaccinations aimed at blocking transmission and enhancing existing vaccines on April 5 at 4:40 p.m. ET. Dr. Cummings will present findings on Vaxart’s oral bivalent norovirus vaccine candidate on April 6 at 12:15 p.m. ET. Vaxart is a clinical-stage biotechnology company focusing on oral recombinant vaccines that do not require refrigeration.
Vaxart, Inc. (NASDAQ: VXRT) will host a key opinion leader (KOL) video webcast on March 28, 2023, at 1:00 p.m. ET, focusing on the health and economic impact of norovirus. The webcast will feature experts Jan Vinjé, Ph.D. from the CDC, and Sarah Bartsch from CUNY. Vaxart's management will discuss their investigational oral pill vaccine for norovirus, detailing two Phase 2 clinical trials. One study aims to assess the efficacy of a GI.1 vaccine candidate, with topline data expected in Q3 2023. Another trial will evaluate vaccine dosing for a possible Phase 3 study, with topline data due mid-2023.
Vaxart (NASDAQ: VXRT) has announced a strategic shift prioritizing its bivalent norovirus vaccine candidate following encouraging clinical trial results. The company has completed six trials demonstrating robust immunogenicity and safety in young adults and the elderly. Vaxart plans to report topline data from ongoing Phase 2 studies in mid-2023 and Q3 2023, respectively. The company ended 2022 with $95.7 million in cash but reported a net loss of $107.8 million, up from $70.5 million in 2021. Vaxart's research and development expenses surged to $81.1 million due to increased headcount and clinical trial costs, while revenue fell to $0.1 million from $0.9 million in 2021.
FAQ
What is the current stock price of Vaxart (VXRT)?
What is the market cap of Vaxart (VXRT)?
